who reports todayUS earnings, drawn as flowsMy portfolio

← Who reports today · Health Care

VTRS · Q2 2026

Archived report (Q2 2026). Latest deep dive →

US GAAP, Q2 2026 · quarter ended 06/30/2026 · released Aug 6

The quarter in brief

Revenue grew 4.9% y⁠/⁠y to $3.76B, operating margin 0.2% vs 6.5%, net loss $119M (vs net loss $4.6M a year earlier).

All figures in $M.

Sankey diagram of VTRS earnings report for Q2 2026: revenue, costs and profitNet sales$3,746 · +5.0%Other revenues$10.9 · −16.8%Total revenues$3,757 · +4.9%Acquired IPR&D$5.8 · vs $0Other (income)expense, net$50.4 · vs −$334Net (loss)earnings$119 · ×26Cost of sales$2,300 · +2.3%Research and development$248 · +13.5%Selling, general andadministrative$1,135 · +22.2%Litigation settlements andother contingencies, net$73.2 · +53.8%Interest expense$121 · +3.5%Income tax provision(benefit)$54.8
Sankey diagram of VTRS earnings report for Q2 2026: revenue, costs and profit
Line itemAmount and change
Net sales$3,746 · +5.0%
Other revenues$10.9 · −16.8%
Total revenues$3,757 · +4.9%
Acquired IPR&D$5.8 · vs $0
Other (income) expense, net$50.4 · vs −$334
Net (loss) earnings$119 · ×26
Cost of sales$2,300 · +2.3%
Research and development$248 · +13.5%
Selling, general and administrative$1,135 · +22.2%
Litigation settlements and other contingencies, net$73.2 · +53.8%
Interest expense$121 · +3.5%
Income tax provision (benefit)$54.8

Verdict: revenue grew 4.9% y/y to $3.76B, operating margin 0.2% vs 6.5%, net loss $119M (vs net loss $4.6M a year earlier).

U.S. GAAP gross margin 38.8% vs 37.2%; approximately $550 million returned to shareholders; gross leverage ratio reduced to 2.9x; 2026 guidance midpoints raised.

Source and notation

Source: Viatris press release, 8-K EX-99.1 of 08/06/2026 (SEC EDGAR). Every figure was matched against the income statement in the release and checked against SEC XBRL.

Open as an image: VTRS, Q2 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0

Cite / embed this chart

Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).

Credit line
Chart: “VTRS Q2 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/vtrs/q2-2026. Licensed under CC BY 4.0.
HTML: image with link and credit
<figure>
  <a href="https://whoreportstoday.com/t/vtrs/q2-2026"><img src="https://whoreportstoday.com/t/vtrs/q2-2026/sankey.png" alt="VTRS Q2 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a>
  <figcaption>Source: <a href="https://whoreportstoday.com/t/vtrs/q2-2026">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption>
</figure>
Direct link to the image (PNG)
https://whoreportstoday.com/t/vtrs/q2-2026/sankey.png
Link for your article text
<a href="https://whoreportstoday.com/t/vtrs/q2-2026">VTRS Q2 2026 earnings chart (Who Reports Today)</a>

This is an archived report: the image at this link won’t change. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.

VTRS — Viatris is a global healthcare company that sells branded and generic medicines, including off-patent brands, across developed and emerging markets.

Headquarters: Canonsburg, Pennsylvania.

Heads-up

More reports: WAT · Q3 2026 · WST · Q3 2026 · ZBH · Q3 2026 · ZTS · Q3 2026 · A · Q3 FY2026 · ABBV · Q3 2026 · ABT · Q3 2026 · ALGN · Q3 2026 · AMGN · Q3 2026 · BAX · Q3 2026 · all reports

Company reports

Q3 2026latest breakdownRevenue $3.75B (−0.3% y/y), operating income $262M (+46.3% y/y), net loss $325M.
Q2 2026Revenue grew 4.9% y/y to $3.76B, operating margin 0.2% vs 6.5%, net loss $119M (vs net loss $4.6M a year earlier).

Cookies the site needs and, with your consent, Google Analytics — privacy policy